W
William W. Busse
Researcher at University of Wisconsin-Madison
Publications - 740
Citations - 62685
William W. Busse is an academic researcher from University of Wisconsin-Madison. The author has contributed to research in topics: Asthma & Eosinophil. The author has an hindex of 115, co-authored 697 publications receiving 56703 citations. Previous affiliations of William W. Busse include National Institutes of Health & University at Buffalo.
Papers
More filters
Journal ArticleDOI
Expression of interleukin-5- and granulocyte macrophage-colony-stimulating factor-responsive genes in blood and airway eosinophils
Mary Ellen Bates,Lin Ying Liu,Stephane Esnault,Barbara A. Stout,Ekokobe Fonkem,Vanderlene L. Kung,Julie B. Sedgwick,Elizabeth A. B. Kelly,Douglas M. Bates,James S. Malter,William W. Busse,Paul J. Bertics +11 more
TL;DR: Several transcriptional targets of IL-5 and GM-CSF in human eosinophils are identified and suggest that a number of protein products are critical to the responsiveness of airway eosInophils.
Journal ArticleDOI
Expert Panel Report 3: Moving forward to improve asthma care.
Journal ArticleDOI
The effects of inhaled budesonide on lung function in smokers and nonsmokers with mild persistent asthma.
TL;DR: Asthmatic patients who smoke, and are not treated with ICSs, have a greater decline in lung function than asthmatic Patients who do not smoke and the benefits of therapy with inhaled budesonide on preventing lung function decline are similar in smokers and nonsmokers with mild persistent asthma.
Journal ArticleDOI
Asthma diagnosis and treatment: Filling in the information gaps
TL;DR: Although the diagnosis of asthma is often based on clinical information, it is important to pursue objective criteria as well, including an evaluation for reversibility of airflow obstruction and bronchial hyperresponsiveness, an area with new diagnostic approaches.
Journal ArticleDOI
Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies
Rohit K. Katial,Greg W. Bensch,William W. Busse,Bradley E. Chipps,Joshua L. Denson,Anthony N. Gerber,Joshua S. Jacobs,Monica Kraft,Richard J. Martin,Parameswaran Nair,Michael E. Wechsler +10 more
TL;DR: This article interprets current evidence for biomarkers of eosinophilic or type 2-high asthma so that clinicians can determine potential treatments for patients based on knowledge of their effectiveness in specific asthma phenotypes and assess clinical data on the efficacy, safety, and mechanisms of action of approved and pipeline biologic therapies.